Current Report Filing (8-k)
June 26 2018 - 8:15AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 26, 2018
ALDEYRA THERAPEUTICS, INC.
(Exact name of Registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
|
|
001-36332
|
|
20-1968197
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
131 Hartwell Avenue, Suite 320
Lexington, MA 02421
(Address of principal executive offices and zip code)
Registrants telephone number, including area code:
(781) 761-4904
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this
chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 7.01. Regulation FD.
On June 26, 2018, Aldeyra Therapeutics, Inc. (Aldeyra) intends to make a slide presentation at its 2018 Research Day in person in New York
City and by webcast on Aldeyras website. A copy of Aldeyras slide presentation is furnished as Exhibit 99.1 to this Current Report on Form
8-K
and is incorporated by reference herein.
The furnishing of the attached slide presentation is not an admission as to the materiality of any information therein. The information contained in the slide
presentation is summary information that is intended to be considered in the context of more complete information included in Aldeyras filings with the Securities and Exchange Commission and other public announcements that Aldeyra has made and
may make from time to time by press release or otherwise. Aldeyra undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate.
The information in Item 7.01 of this Form
8-K
shall not be deemed filed for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific
reference in such a filing, regardless of any general incorporation language in any such filing, unless Aldeyra expressly sets forth in such filing that such information is to be considered filed or incorporated by reference therein.
Item 8.01 Other Events.
On June 26, 2018,
Aldeyra issued a press release that provided an update on Aldeyras clinical development plans and pipeline. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form
8-K
and
is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
ALDEYRA THERAPEUTICS, INC.
|
|
|
By:
|
|
/s/ Todd C. Brady, M.D., Ph.D.
|
|
|
Name: Todd C. Brady, M.D., Ph.D.
|
|
|
Title: President and Chief Executive Officer
|
Dated: June 26, 2018
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Sep 2023 to Sep 2024